Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.

By A. Suetsugu, M. Nagaki, H. Aoki, T. Motohashi, T. Kunisada, H. Moriwaki. Biochemical and Biophysical Research Communications - BBRC, 2006

633 citations recorded by the source corpus.

Subfields: Biotechnology, Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/e3a2ab9e2bba58e337768c59918db5bc98113a7f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Weinberg

In Oncology

1. A. Puisieux
2. R. Weinberg

Citations in the corpus

• CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway (2008, background): “Further, CD133 represents only a minority of the tumor cell population in human HCC specimens (Suetsugu et al., 2006; Ma et al., 2007; Yin et al., 2007).”
• Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition (2008, background): “Over the past few years, candidate cancer stem cells have been identified in a variety of human malignancies including leukemias and a number of solid tumors such as glioblastomas, medulloblastomas and carcinomas [11–24].”
• Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer (2009, background): “including circulating fibrocytes (17, 21), thus limiting its application in enriching lung CSCs (6).”